Prior reports have linked patient transmission of carbapenem-resistant Enterobacteriaceae (CRE, or "superbug") to endoscopes used during endoscopic retrograde cholangiopancreatography (ERCP). We performed a decision analysis to measure the cost-effectiveness of four competing strategies for CRE risk management.
INTRODUCTION
Over 500,000 endoscopic retrograde cholangiopancreatographies (ERCPs) are performed annually in the United States for diagnostic and therapeutic indications ( 1 ) . ERCP is the gold standard for the management of a variety of disorders, including symptomatic common bile duct (CBD) stones, biliary cholangitis, and pancreatic and biliary malignancy ( 2 ) . Unique to ERCP is the duodenoscope, an endoscope with an elevator channel that allows for the placement of guidewires, catheters, and other endoscopic accessories into the operator's visual fi eld. Although the design of this endoscope permits technically advanced and precise biliary procedures, the diffi cult to access elevator channel poses a challenge for eff ective duodenoscope reprocessing and decontamination.
Contaminated endoscopes cause more healthcare-associated infection outbreaks than any other medical device ( 3, 4 ) . In most cases, these infections are caused by intestinal fl ora, predominantly Enterobacteriaceae and Enterococcus ( 4, 5 ) . Although some outbreaks have been associated with inadequate reprocessing of endoscopes, epidemics have occurred even without lapses in decontamination procedures (6) (7) (8) (9) (10) (11) (12) (13) (14) . Th e most serious of these epidemics are those caused by multidrug-resistant organisms (MDRO), including carbapenem-resistant Enterobacteriaceae (CRE), one of the resistant bacteria termed "superbugs" in the lay media. Th ere are limited treatment options for MDRO and CRE infections, and multiple recent CRE outbreaks associated with contaminated duodenoscopes have been the focus of widespread media attention, including at our own institutions ( 15, 16 ) .
Th e most cost-eff ective approach for preventing CRE transmission remains uncertain. In March 2015, the US Food and Drug Administration (FDA) released a safety communication detailing new reprocessing instructions for duodenoscopes, which includes additional brushing of the forceps elevator recess area with a new smaller bristle cleaning brush, among other steps ( 17 ) . Some medical centers have also adopted a "culture and hold" approach where duodenoscopes are cultured aft er ERCP and held until cultures are negative for 48 h ( 13 ) . Others have turned to ethylene oxide (EtO) gas sterilization ( 6, 14 ) , a process that is believed to off er optimal endoscope sterilization but is costly and typically requires outsourcing. Another potential option is to halt the use of ERCP in favor of surgical and interventional radiology procedures. In this study, we performed a decision analysis to measure the cost-eff ectiveness and healthcare impact of these competing strategies for CRE risk management.
METHODS

Model overview
We used decision analysis soft ware (TreeAge Pro, version 2014, TreeAge Soft ware, Inc, Williamstown, MA) to evaluate a hypothetical cohort of patients hospitalized for symptomatic CBD stones, the most common indication for ERCP ( 2 ) . To emulate a case mix in clinical practice, we assumed that some individuals with symptomatic CBD stones had concomitant obstructive jaundice and cholangitis. In 2012, 23% of US hospitalizations principally for CBD stones were complicated by cholangitis ( 18 ) . Individuals entered the hypothetical model without previous intervention and underwent one the of four competing strategies: (1) perform ERCP followed by FDA-recommended endoscope reprocessing procedures; (2) perform ERCP followed by "endoscope culture and hold"; (3) perform ERCP followed by EtO sterilization of the endoscope; or (4) stop ERCP and perform laparoscopic cholecystectomy (LC) with CBD exploration (CBDE). We then followed the cohort over the course of a 1-year time horizon. During this time, it was assumed that there was no mortality from competing but unrelated causes. Figure 1 displays the truncated decision model. We assumed that all duodenoscopes were previously used in patients without a known, culture-confi rmed history of CRE. In other words, our model assumed that some individuals were unrecognized CRE carriers and unknowingly transferred CRE to the duodenoscope. We chose to not include patients previously recognized as CRE carriers, as duodenoscopes used in these cases in real clinical practice are likely to undergo more aggressive reprocessing (i.e., EtO sterilization) and surveillance. Th is would subsequently lower the pretest probability of the duodenoscope harboring CRE.
Model assumptions
We assumed that all patients who underwent ERCP were at risk for acquiring CRE. Th ose who acquired CRE and developed clinical symptoms consequently required readmission to the hospital for management of CRE sepsis; all point sources of CRE sepsis (e.g., cholangitis, bacteremia, urinary, pulmonary, etc.) were considered equivalent. We assumed patients with a clinical CRE infection presented back to the hospital within 30 days of the ERCP ( 6 ) . On the basis of prior reports, we estimated that CRE sepsis had a case fatality rate of 43% ( 7, 13, 16, 19, 20 ) . Because of the lack of data on the natural history and long-term consequences of CRE carriage, we used a 1-year time horizon for this study.
We also assumed that all individuals who received an ERCP subsequently underwent an outpatient LC. Th ose who did not develop a symptomatic CRE infection had an outpatient LC 6 weeks aft er their initial hospitalization for symptomatic CBD stones ( 21 ) . Patients with CRE sepsis had an outpatient LC 6 weeks aft er their associated hospitalization for CRE.
Competing strategies
ERCP with only FDA-recommended reprocessing procedures strategy . Th is strategy served as our referent case for the analysis. For all ERCP-based strategies, we assumed that hospitalized patients with symptomatic CBD stones±cholangitis were managed similarly with an ERCP with clearance of the CBD and sphincterotomy. Duodenoscopes then underwent high-level disinfection (HLD) adhering to the FDA-recommended reprocessing instructions issued in March 2015 ( 17 ) . Key changes include additional brushing of the forceps elevator recess area with a new smaller bristle cleaning brush, additional fl ushing of the forceps elevator recess area, and additional manual fl ushing steps and increased fl ushing volume of the channels, among other steps ( 17 ) .
Of note, the FDA released another safety communication in August 2015 that recommended repeat HLD (i.e., "double wash") as a viable option for reprocessing duodenoscopes ( 22 ) . However, there is no data regarding whether repeat HLD is more effi cacious than single HLD at clearing CRE and other MDRO. Because of this combined with the fact that repeat HLD costs minimally more than single HLD ($68.55 per HLD, see Supplementary Table S1 online), we chose to not include "double wash" as a separate arm in our decision analysis. FDA-recommended reprocessing guidelines ( 17 ) . Aft erward, the duodenoscopes were cultured and sequestered until cultures were negative for growth aft er 48 h ( 13 ) . Duodenoscopes with positive cultures underwent a second HLD and were then subsequently recultured and held pending negative culture results. For the purposes of this analysis, we assumed that duodenoscopes with two successive cultures positive for "high-concern" bacteria ( 23 ), despite appropriate reprocessing, were sent to an outside facility for EtO sterilization. Given the minimum 48-h turnaround time for culture results, additional duodenoscopes must be purchased at the outset of the study in order to maintain the same throughput in the endoscopy unit. Here we assumed that the base-case institution performed 1000 ERCPs per year and had four duodenoscopes (consistent with a high-volume center). Assuming that four ERCPs were performed each weekday, we assumed that eight new duodenoscopes would need to be purchased to ensure that clinical fl ow was uninterrupted.
ERCP followed by EtO sterilization strategy . Hospitalized patients in this arm fi rst underwent ERCP with clearance of the CBD and sphincterotomy. Duodenoscopes were then disinfected using the FDA-recommended reprocessing guidelines ( 17 ) . As most institutions do not off er in-house EtO sterilization, we assumed that EtO sterilization of the duodenoscope was outsourced and performed at an outside facility. We also assumed at least a 48-hour turnaround time (i.e., time required for the EtO sterilization and transport back and forth between the endoscopy unit and EtO sterilization provider) before the duodenoscopes could be used again; this requires eight additional duodenoscopes be purchased at the beginning of the study. Moreover, on the basis of reports that EtO can damage duodenoscopes ( 4 ), we performed a sensitivity analyses assuming that EtO exposure would require more frequent purchase of replacement scopes.
Stop ERCP and perform LC with CBDE strategy . In this strategy, treatment for hospitalized patients was stratifi ed by the presence of cholangitis. Th ose presenting with symptomatic CBD stones without cholangitis underwent a LC with CBDE. Th ose with concomitant cholangitis fi rst underwent percutaneous transhepatic cholangiography with biliary tube placement followed by an inpatient LC with CBDE the next day.
Clinical probability estimates
Our base-case model incorporated a wide range of estimates governing relevant clinical probabilities in the management of symptomatic CBD stones ( Table 1 ). To derive these estimates, we primarily used data published in the Cochrane Database of Systematic Reviews. When such reviews were unavailable, we retrieved pertinent studies in MEDLINE and used a weighted average of estimates when multiple studies were identifi ed. Table 1 also lists our base-case CRE clinical and prevention strategy probability estimates. Because there are limited data and uncertainty regarding these estimates, we conducted a number The model accounted for procedure-related complications and mortality. Patients who had an ERCP were at risk for acquiring CRE; those who did not develop an overt CRE infection had an outpatient LC 6 weeks after their initial hospitalization. Those who developed CRE sepsis consequently required readmission to the hospital; patients who survived were discharged and had an outpatient LC 6 weeks later. For the surgery-based approach, treatment was stratifi ed by the presence of cholangitis, as those with cholangitis fi rst had PTC tube placement prior to LC with CBDE. CBD, common bile duct; CBDE, common bile duct exploration; CRE, carbapenem-resistant Enterobacteriaceae; ERCP, endoscopic retrograde cholangiopancreatography; EtO, ethylene oxide; FDA, Food and Drug Administration; LC, laparoscopic cholecystectomy; PTC, percutaneous transhepatic cholangiography. A full color version of this fi gure is available at the American Journal of Gastroenterology journal online.
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Outcomes
We used quality-adjusted life years (QALYs) as our main outcome measure, and our analysis reported the incremental cost per QALY gained among the four competing strategies. We also reported the 2.5th and 97.5th percentiles around the point estimates as generated by a Monte Carlo analysis of 1,000 trials (see Sensitivity Analyses section for details). For our analyses, $100,000 per QALY gained was chosen as our cost-eff ective threshold; we opted to use $100,000 per QALY gained rather than the traditionally used $50,000 per QALY, as prior reports have found that the latter is too low for the US (24) (25) (26) .
Utility estimates
Th e model included a wide range of relevant health state utilities for symptomatic CBD stones, procedure-related complications, and CRE infection. Th e Tuft s Cost-Eff ectiveness Analysis Registry was searched to identify pertinent utilities ( Table 1 ) ( 27 ) . As our study cohort was followed over a 1-year period, discounting was not performed.
Cost estimates
Th e model accounted for total health-care costs attributable to the competing strategies, both from the payer and the hospital perspective. Table 2 depicts all the base-case costs estimates used in our study, and Supplementary Table S1 describes these estimates in detail. Costs associated with hospital admissions were obtained from the Healthcare Cost and Utilization Project database ( 18 ) . We obtained costs for physician services and procedures using the 2015 American Medical Association Current Procedural Terminology codebook and the 2015 Medicare Physician Fee Schedule ( 28, 29 ) . We also incorporated the direct health-care costs associated with each ERCP reprocessing strategy (e.g., FDA-recommended reprocessing, new and replacement duodenoscopes, cultures, and EtO sterilization). All estimates were updated to 2015 US dollars by using the Consumer Price Index infl ation calculator ( 30 ) . As our study cohort was followed over a 1-year period, discounting was not performed.
Sensitivity analyses
Because there are limited data regarding the CRE-related clinical probability estimates as well as the eff ectiveness of the proposed CRE-prevention strategies, we conducted extensive one-way sensitivity analyses for each estimated probability, ranging variables from 0 to 100%. In our base-case model, we assumed that endoscopes in the EtO sterilization strategy were sent to an outside facility, but some institutions have in-house facilities that perform such sterilization. Th us, we also performed a sensitivity analysis accounting for this scenario, as it precludes the need to purchase additional endoscopes at the outset and for courier costs.
We also conducted a Monte Carlo simulation, assuming that all variables followed a triangular distribution with base-case, minimum, and maximum values listed in Tables 1 and 2 . One Clinical probabilities, % Pretest probability of CRE-infected endoscope a 1 (0-10) CRE transmission after ERCP with infected endoscope ( 6, 7, 14 ) 31 Patient with CRE develops clinical symptoms ( 7, 14 ) 73 (25-100) CRE-related mortality ( 7, 13, 16, 19, 20 ) 43 ( . Th e strategy in which ERCP is discontinued in lieu of performing LC with CBDE was dominated by the alternative strategies, as it was both more expensive and marginally less eff ective.
Base-case sensitivity analyses
Because of limited data regarding the probability estimates for CRE clinical and prevention strategies, we performed extensive sensitivity analyses ( Table 3 ) . Interestingly, the model was insensitive to most of the variables for which an accurate estimate was not available. For example, when setting the eff ectiveness of FDArecommended reprocessing at 0% (i.e., testing the status quo prior to implementation of FDA-recommended reprocessing procedures), we found that the other competing approaches were still cost-prohibitive. However, a few thresholds were noted. For instance, when the pretest probability of CRE exceeded 24%, ERCP with culture and hold became the most cost-eff ective strategy (i.e., incremental cost per QALY gained <$100,000) compared with ERCP with FDArecommended reprocessing. If the total cost associated with EtO thousand trials were simulated, and we analyzed the base-case cohort to fi nd the 2.5th and 97.5th percentiles for our estimate of incremental cost per QALY gained among competing strategies. We also used results from the Monte Carlo simulation to generate a cost-eff ectiveness acceptability curve plot of the four competing strategies and tested willingness to pay thresholds ranging from $0 to $200,000 per QALY gained.
RESULTS
Base-case results
Among the four competing strategies, the least expensive was ERCP with FDA-recommended reprocessing procedures Table 3 . Because some institutions have in-house facilities that perform EtO sterilization, we performed a sensitivity analysis that accounted for a 24-hour endoscope turnaround time. Th is obviates the need to purchase additional endoscopes at the outset as well as courier costs. Even in this scenario, in-house EtO sterilization was still cost-prohibitive ($7,478,728 per QALY gained; 2.5th and 97.5th percentiles, $176,221 and $26,051,419, respectively) compared with ERCP with FDA-recommended reprocessing. Figure 3 depicts the cost-eff ectiveness acceptability curve plot for the four competing approaches in 1,000 simulations across a tested willingness to pay range from $0 to $200,000 per additional QALY. At a willingness to pay threshold of $100,000 per QALY gained, most trials favored ERCP with FDA-recommended reprocessing as the most cost-eff ective approach (82.6%), followed by LC with CBDE (15.6%), ERCP with culture and hold (1.7%), and ERCP with EtO sterilization (0.1%). Results were similar when using a higher willingness to pay threshold of $200,000 per QALY (ERCP with FDA-recommended reprocessing, 72.5%; LC with CBDE, 23.1%; ERCP with culture and hold, 4.3%; and ERCP with EtO sterilization, 0.1%).
Monte Carlo analyses
DISCUSSION
In light of several recent ERCP-associated CRE ("superbug") outbreaks across the US ( 6,13-16 ), we performed a comprehensive decision analysis to identify the most cost-eff ective approach to endoscope reprocessing. Our analysis has four key fi ndings. First, we found that the use of FDA-recommended reprocessing procedures aft er ERCP was the most cost-eff ective approach for mitigating CRE transmission. As the overall incidence of clinically overt CRE transmission via ERCP appears to be rare, the diff erences in QALYs between the four competing strategies were extremely small. Because the overall eff ectiveness among strategies was similar, diff erential cost is the principal factor driving the health economic interpretation.
Second, we demonstrated that results were highly contingent on the pretest probability for CRE. Th e FDA-recommended reprocessing strategy was the most cost-eff ective strategy until the CRE pretest probability exceeded 24%. At that point, the culture and hold strategy became more cost-eff ective. Given the low positiveculture rate for "high-concern" bacteria in endoscope studies ( 13 ) . it is highly unlikely that CRE carriage rates will exceed 24% in the near future. However, as the usage of potent antibiotics continues, it is possible that the prevalence of CRE and other "superbugs" may approach this threshold, particularly in high-volume, quaternary-care centers. At that time, these health-care centers and endoscopy units may benefi t from utilizing culture and hold as a more cost-eff ective approach to reducing the risk of CRE remains low, it is unlikely that the more invasive LC with CBDE will supplant ERCP as the preferred modality for managing symptomatic choledocholithiasis. Th ere have also been concerns about insuffi cient exposure and training among general surgery residents in performing CBDE ( 31 ) . Th is analysis has limitations. First, the CRE-related clinical and prevention strategy estimates used in the model were based on limited data. Specifi cally, the pretest probability for CRE and the eff ectiveness of FDA-recommended reprocessing, culture and hold, and EtO sterilization at preventing CRE transmission are unknown at this time, yet strongly impact the results. To address this, we tested a wide range of potential values for the CRE-related probability estimates in both 1-way sensitivity and Monte Carlo analyses. Here we found that the cost-eff ectiveness rankings were robust to sensitivity analyses. Second, our model did not account for legal costs related to CRE cases from infected duodenoscopes. Namely, lawsuits have been fi led against some institutions with such cases ( 32, 33 ) . Factoring in legal costs is problematic given that legal fees, settlements, and patient compensation vary widely. Legal costs are also not exclusive to cases of CRE, as lawsuits can be fi led aft er complications from ERCPs and surgical interventions. Our model also did not account for costs associated with negative publicity from cases of CRE transmission. Similar to legal issues, it is diffi cult to assign a cost to negative press, as its impact (e.g., decreased referrals, cancellation of elective procedures, etc.) will vary widely between institutions. Because of these inherent issues we opted to not include costs associated with litigation or poor publicity in our decision analysis. However, for institutions that anticipate exorbitant legal costs or damaging negative press from CRE cases, employing FDA-recommended reprocessing (the "least
transmission. Yet, we should note that the culture and hold strategy may pose potential logistic challenges, particularly at stand-alone endoscopy centers. Namely, these units may not have in-house laboratory facilities or may only have access to a facility that lacks on-site experience with the duodenoscope culturing and interpretation of results ( 22 ) .
Th ird, we found that using EtO gas sterilization was unlikely to be cost-eff ective under any circumstances. Although EtO gas sterilization is believed to off er optimal endoscope sterilization, its impact on reducing CRE transmission has not been formally tested in a clinical trial. Yet, there is anecdotal evidence that it is eff ective, as no additional cases of CRE were found-to datein hospitals that implemented EtO sterilization aft er having had CRE outbreaks linked to ERCPs ( 6, 14 ) . Along the same lines, there are currently no published, randomized controlled data demonstrating the eff ectiveness of the FDA-recommended reprocessing and culture and hold strategies for preventing CRE transmission. Th us, while awaiting additional data, endoscopy centers that opt out of EtO sterilization may need to assume an unavoidable, low level of CRE risk. Th is may be unacceptable, though, for institutions with a known, relatively high CRE prevalence or that have patients infected with CRE linked to recently performed ERCPs.
Fourth, although we found that LC with CBDE was dominated in the base-case scenario, Monte Carlo analyses revealed that it was cost-eff ective in approximately 15% of trials at a willingness to pay threshold of $100,000 per QALY. Th is is likely a refl ection of the greater uncertainty in the clinical probability estimates used in the ERCP-based strategies vs. those used in the surgical arm. However, in real clinical practice where the prevalence of CRE 
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eff ective" ERCP-based approach) may not be a reasonable option, particularly among institutions with prior cases of CRE. Rather, culture and hold or EtO sterilization may be the only viable strategies for these establishments. Th ird, our fi ndings may not be generalizable to all indications for ERCP. Our hypothetical cohort was in patients with symptomatic CBD stones, only one of the many conditions where ERCP is strongly indicated. Nonetheless, our base-case cohort refl ects the most common indication for ERCP ( 2 ); therefore, it is the most appropriate condition on which to base a cost-eff ectiveness analysis. By using a common condition in the base-case model, we have tried to generate results that are relevant to most settings where ERCP is performed. Fourth, our study focuses primarily on CRE and does not assess the impact of other MDROs. Just as there are limited data for CRE, there are even less data on the clinical impact of other MDROs transmitted during ERCP. Th is is an area worth investigating further. Finally, our study does not account for screening of patients for CRE/MDRO prior to ERCP; this may identify duodenoscopes at "high-risk" for harboring such organisms, thereby singling them out for more aggressive reprocessing and surveillance. However, the FDA has not yet recommended this as a viable approach for mitigating MDRO risk, and it is not clear as to which MDROs should be tested for and which are clinically relevant.
In conclusion, our analysis suggests that of the four strategies examined, ERCP with FDA-recommended reprocessing is the most cost-eff ective approach for mitigating CRE risk. Only when the CRE pretest probability exceeds rates much higher than currently reported does ERCP with culture and hold become potentially cost-eff ective. Future research should formally investigate the eff ectiveness of CRE-elimination using these methods and determine whether other reprocessing strategies should be considered. CRE infections have become the object of intensive popular media scrutiny and a frequent source of patient concern. In light of the current uncertainty regarding the best management of CRE risk, limited treatment options for CRE-infected patients, and high mortality associated with CRE infection, our results may assist health-care administrators, health-care centers, and endoscopy clinics in deciding how to reduce CRE risk for what can otherwise be a life-saving procedure.
